SEC Form 4 · accession 0001213900-26-072789
Cadrenal Therapeutics, Inc. · CVKD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Quang X Pham
Officer — Chairman, CEO and Interim CFO · Director · 10% Owner
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 8:44 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001937993
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 25, 2026 | S | 2,127 | $3.00 | D | 115,018 | D | |
| Common StockF1,F2 | Jun 26, 2026 | S | 9,029 | $3.05 | D | 105,989 | D | |
| Common StockF3 | holding | — | — | — | 200,000 | I | The PVBQ Living Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.